Fairvalue-Calculator Fairvalue-Calculator

SCHOTT Pharma AG (SHTPY) Fair Value & Analysis

Healthcare · US · Market cap $2.7B

Price$4.37
Fair Value$3.34
Upside-23.6%
Quality97/100
Evidence: High Range $2.88 – $5.44

Analysis

SCHOTT Pharma AG (SHTPY) currently trades at $4.37, while our model-based Fair Value estimate is $3.34 — implying the stock looks roughly 23.6% overvalued today. We read business quality at 97/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; SCHOTT TOPPAC unique, a polymer container; and SCHOTT TOPPAC cartridge. It also provides pharmaceutical glass cartridge, such as cartriQ for peptide and protein-based injectables; cartriQ Large Volume for large-volume injectables; Cartridges Double Chamber for lyophilized drugs; Cartridges Break Resistant; and TopLin…

Open the full interactive analysis →

Similar stocks

Intuitive Surgical, Inc (ISRG) -55% EssilorLuxottica Société anonyme (ESLOF) -44% HOYA Corporation (HOCPY) -43% Medline Inc (MDLN) -13% Becton, Dickinson and Company (BDX) -28% Alcon Inc (ALC) -33%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.